The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

NCT05943821 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1116

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases
Uric Acid

Interventions

DRUG: Allopurinol 200 mg
DRUG: Optional intervention

Sponsor

Poznan University of Medical Sciences